IL24 and breast carcinoma: Likewise, other studies have documented that the administration of IL‐24 results in decreased invasive and migratory capacity in Ishikawa cells (Liao et al. 2020) as well as MDA‐MB‐231 breast cancer cells (Patani et al. 2010).